Buenos Aires - Delayed Quote • ARS
GSK plc (GSK.BA)
As of April 24 at 4:59 PM GMT-3. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
30,328,000.00
30,328,000.00
29,324,000.00
24,696,000.00
24,354,000.00
Cost of Revenue
8,565,000.00
8,565,000.00
9,554,000.00
8,163,000.00
7,929,000.00
Gross Profit
21,763,000.00
21,763,000.00
19,770,000.00
16,533,000.00
16,425,000.00
Operating Expense
14,418,000.00
14,418,000.00
13,041,000.00
11,655,000.00
11,847,000.00
Operating Income
7,345,000.00
7,345,000.00
6,729,000.00
4,878,000.00
4,578,000.00
Net Non Operating Interest Income Expense
-735,000.00
-735,000.00
-826,000.00
-755,000.00
-852,000.00
Pretax Income
6,064,000.00
6,064,000.00
5,628,000.00
3,599,000.00
5,170,000.00
Tax Provision
756,000.00
756,000.00
707,000.00
83,000.00
67,000.00
Net Income Common Stockholders
4,928,000.00
4,928,000.00
14,956,000.00
4,385,000.00
5,749,000.00
Diluted NI Available to Com Stockholders
4,928,000.00
4,928,000.00
14,956,000.00
4,385,000.00
5,749,000.00
Basic EPS
0.61
0.61
1.86
0.55
0.72
Diluted EPS
0.60
0.60
1.83
0.54
0.71
Basic Average Shares
8,104,000.00
8,104,000.00
8,052,000.00
8,006,000.00
7,961,600.00
Diluted Average Shares
8,222,000.00
8,222,000.00
8,168,000.00
8,104,000.00
8,060,800.00
Total Operating Income as Reported
6,745,000.00
6,745,000.00
6,433,000.00
4,357,000.00
5,979,000.00
Rent Expense Supplemental
27,000.00
27,000.00
17,000.00
20,000.00
27,000.00
Total Expenses
22,983,000.00
22,983,000.00
22,595,000.00
19,818,000.00
19,776,000.00
Net Income from Continuing & Discontinued Operation
4,928,000.00
4,928,000.00
14,956,000.00
4,385,000.00
5,749,000.00
Normalized Income
5,401,553.43
5,401,553.43
4,494,705.22
3,349,189.00
3,071,343.00
Interest Income
48,000.00
48,000.00
31,000.00
11,000.00
17,000.00
Interest Expense
725,000.00
725,000.00
826,000.00
764,000.00
847,000.00
Net Interest Income
-735,000.00
-735,000.00
-826,000.00
-755,000.00
-852,000.00
EBIT
6,789,000.00
6,789,000.00
6,454,000.00
4,363,000.00
6,017,000.00
EBITDA
9,083,000.00
9,083,000.00
8,601,000.00
6,485,000.00
8,067,000.00
Reconciled Cost of Revenue
8,565,000.00
8,565,000.00
9,554,000.00
8,163,000.00
7,929,000.00
Reconciled Depreciation
2,294,000.00
2,294,000.00
2,147,000.00
2,122,000.00
2,050,000.00
Net Income from Continuing Operation Net Minority Interest
4,928,000.00
4,928,000.00
4,256,000.00
2,805,000.00
4,464,000.00
Total Unusual Items Excluding Goodwill
-541,000.00
-541,000.00
-273,000.00
-557,000.00
1,411,000.00
Total Unusual Items
-541,000.00
-541,000.00
-273,000.00
-557,000.00
1,411,000.00
Normalized EBITDA
9,624,000.00
9,624,000.00
8,874,000.00
7,042,000.00
6,656,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-67,446.57
-67,446.57
-34,294.78
-12,811.00
18,343.00
12/31/2020 - 12/27/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade